WGI-0301 plus nivolumab for liver and kidney cancers
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called WGI-0301 combined with the immunotherapy nivolumab for people with advanced liver cancer (HCC) or certain types of kidney cancer (RCC). The goal is to see if this combination can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced liver cancer (HCC) that has not responded to first-line treatment, or kidney cancer (RCC) that is either advanced and untreated (nccRCC) or has progressed after first-line therapy (ccRCC).
- For liver cancer, your liver function must be well enough (Child-Pugh class A or B with score 7 or less).
- You need to be in generally good health (able to perform daily activities with minimal help, life expectancy over 12 weeks).
- You must have at least one tumor that can be measured on scans and that hasn't been treated with local therapy like radiation.
- You must have adequate organ function, including healthy blood counts, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new combination of two drugs—WGI-0301 and lenvatinib—to treat advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed. It's designed for patients whose cancer has progressed despite prior treatments.
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.